Separation, identification of uremic middle molecules, and preliminary study on their toxicity

Li, Guohua; Chu, Jiegen; Liu, Xiaohang; Yuan, Zhi

doi:10.1016/j.cccn.2004.07.003

Cited by 11 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Li et al [110] examined urine and serum samples from uremic patients and healthy subjects using LC and MALDI-TOF MS as well as LC/ESI-MS/MS to define uremic toxins. One of the identified molecules, an octapeptide with molecular weight 1,007.94 Da (Val-Val-ArgGly-Cys-Thr-Trp-Trp), was biologically active; it accelerated the death of rabbits with chronic renal failure.…”

Section: Identification Of Uremic Toxins Using Proteomicsmentioning

confidence: 99%

High‐resolution proteome/peptidome analysis of peptides and low‐molecular‐weight proteins in urine

Mischak

Julian

Novák

2007

Proteomics Clinical Apps

View full text Add to dashboard Cite

All organisms contain thousands of proteins and peptides in their body fluids. A deeper insight into the functional relevance of these polypeptides under different physiological and pathophysiological conditions and the discovery of specific peptide biomarkers would greatly enhance diagnosis and therapy of specific diseases. The low-molecular-weight proteome, also termed peptidome, provides a rich source of information. Due to its unique features, the technical challenges differ somewhat from those in "common" proteomics. In this manuscript, we focus on the low-molecular-weight urinary proteome. We review the methodological aspects of sample collection, preparation, analysis, and subsequent data evaluation. In the second part of this review, we summarize the recent progress in the definition and identification of clinically relevant polypeptide markers.

show abstract

Section: Identification Of Uremic Toxins Using Proteomicsmentioning

confidence: 99%

High‐resolution proteome/peptidome analysis of peptides and low‐molecular‐weight proteins in urine

Mischak

Julian

Novák

2007

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“…This is consistent with other observations indicating the presence of toxins in uremic plasma, including peptides derived from the process of metabolism. 4,15 However, it should be emphasized, that some of these peptides (marked as 1, 4, 5, and 84) were also present in elevated amounts in sera of hemodialyzed patients before hemodialysis. This indicates that within the interdialysis period these peptides are accumulated effectively in the plasma of hemodialyzed patients.…”

Section: Discussionmentioning

confidence: 99%

Effect of Uremia and Hemodialysis on Proteome Profile of Blood Platelets and Plasma

Walkowiak

Sobol

Walczyńska

et al. 2012

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

The aim of the present research was to assess the differences in blood platelet and plasma proteome profiles of patients with uremia in comparison with healthy participants. It was found that 23 peptides in the platelet proteome profiles of hemodialyzed patients and only 6 peptides in nondialyzed patients were upregulated. On the other hand, 18 peptides with reduced expression in nondialyzed patients and only 1 peptide in hemodialyzed patients were found. For serum, only 6 upregulated peptides in patients undergoing hemodialysis and 15 peptides in nondialyzed patients were found, most of these were about 10 kDa. A decrease in serum peptide expression was not observed. In conclusion, it should be noted that the process of hemodialysis modifies the platelet proteome to a greater extent than uremia alone, however the sera of nondialyzed patients have much larger amounts of low-molecular-weight peptides than those of hemodialyzed patients.

show abstract

“…Li et al [45] found 17 endogenous middle molecular compounds in uremic plasma and normal urine, and identified an octapeptide (1007.94 Da) with an amino acid sequence of Val-Val-Arg-Gly-CysThr-Trp-Trp by using gel permeation chromatography, ion exchange chromatography, and reversed-phase HPLC and MS.…”

Section: Middle-molecular-weight Peptidesmentioning

confidence: 98%

Recent progress in the analysis of uremic toxins by mass spectrometry

Niwa

2009

Journal of Chromatography B

View full text Add to dashboard Cite

Separation, identification of uremic middle molecules, and preliminary study on their toxicity

Cited by 11 publications

References 4 publications

High‐resolution proteome/peptidome analysis of peptides and low‐molecular‐weight proteins in urine

High‐resolution proteome/peptidome analysis of peptides and low‐molecular‐weight proteins in urine

Effect of Uremia and Hemodialysis on Proteome Profile of Blood Platelets and Plasma

Recent progress in the analysis of uremic toxins by mass spectrometry

Contact Info

Product

Resources

About